scholarly journals COMPREHENSIVE ASSESSMENT OF ENDOTHELIUM-DEPENDENT MEDIATORS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION AND DIABETES MELLITUS TYPE 2

2021 ◽  
Vol 76 (2) ◽  
pp. 14-18
Author(s):  
T. S. Zaikina ◽  
P. G. Kravchun ◽  
D. V. Minukhina ◽  
D. V. Minukhin ◽  
D. O. Yevtushenko ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Carbohydrate Metabolism ◽  
Negative Impact ◽  
Enzyme Linked Immunosorbent Assay ◽  
Gradual Improvement ◽  
Type 2 Dm ◽  
Pai 1

The aim of study is to evaluate the levels of endothelium-dependent mediators: endothelial nitric-oxide synthase (NOS), plasminogen activator inhibitor-1 (PAI-1) and circulating soluble CD40 ligand (sCD40L) in patients with acute myocardial infarction (AMI) and concomitant type 2 diabetes mellitus (DM). The study included 255 patients with AMI, who were divided into two groups depending on the presence of concomitant type 2 DM: 1 group — 143 patients with concomitant type 2 DM; 2 group — 112 patients without concomitant disturbances of carbohydrate metabolism. Studied endothelial-dependent indicators were investigated using enzyme-linked immunosorbent assay. Statistical data were processed using the Mann–Whitney U-test, quantitative variables were described by the following parameters: median (Me), 25th and 75th percentiles (Q1; Q3). Analyzing the studied indicators on admission of patients to the hospital, a statistically significant decrease in NOS levels (p < 0,01), as well as an increase in PAI-1 (p < 0,01) and sCD40L (p < 0,01) in the cohort of patients with AMI and concomitant type 2 DM compared with patients without disturbances of carbohydrate metabolism. This indicates a more significant violation of endothelium-dependent vasodilation, thrombin fibrinolysis and activation of intravascular inflammation caused by comorbidity. Over the next 10 days, an increase in NOS levels, a decrease in PAI-1 and sCD40L levels were observed in patients of both groups, indicating a gradual improvement of the endothelial function. However, in patients with AMI and concomitant type 2 DM, the levels of the studied endothelium-dependent mediators continued to differ statistically even on the 10th day after acute occlusion of the coronary artery. In our opinion, this tendency is caused by the negative impact of metabolicdisorders associated with type 2 DM on the endothelium of the coronary arteries in patients with insulin resistance and, apparently, may increase the risk of complications of AMI.

scholarly journals Asymmetric dimethylarginine – a marker of repeated cardiovascular events in patients with comorbid pathology

2021 ◽  
Vol 25 (4) ◽  
pp. 567-571
Author(s):  
D. A. Feldman
Keyword(s):  
Diabetes Mellitus ◽  
Myocardial Infarction ◽  
Type 2 Diabetes ◽  
Acute Myocardial Infarction ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Events ◽  
Asymmetric Dimethylarginine ◽  
Type 2 Dm

Annotation. Today, diseases of the cardiovascular system retain their leading position among the incidence in the world. The presence of comorbid pathology in the form of type 2 diabetes mellitus (DM) significantly complicates the course of these diseases, worsening its prognosis. The aim of the study: to analyze the prognostic value of asymmetric dimethylarginine (ADMA) as a marker of recurrent cardiovascular events in patients with acute myocardial infarction with type 2 diabetes for 6 months of follow-up. 120 patients were examined: group 1 – patients with acute myocardial infarction (AMI) in combination with type 2 diabetes mellitus (n=70), group 2 - patients with isolated AMI (n=50). The control group included 20 practically healthy individuals. All patients underwent general clinical and instrumental examinations, on the first day of AMI the level of ADMA was determined using a commercial test system "Human Asymmetrical Dimethylarginine ELISA". Statistical processing of the obtained data was performed using the software package StatSoft Inc, USA – "Statistica 6.0". The analysis of the average level of ADMA showed a significantly higher value of this indicator in patients with AMI in combination with type 2 DM than in patients without concomitant type 2 DM 2.57 times (1.57±0.11 μmol / l and 0.61±0.06 μmol / l, respectively), (p<0,05. ADMA level >1,72 μmol / l in patients with AMI in combination with type 2 DM and >0,69 μmol / l in patients with AMI without concomitant type 2 DM was identified as a predictor of recurrent acute myocardial infarction within 6 months of follow-up. Thus, the level of ADMA was higher in the presence of comorbid pathology in the form of type 2 DM in patients with AMI, reflecting endothelial dysfunction combining disease. It is advisable to further study this indicator of endothelial dysfunction as a predictor of the adverse course of AMI in combination with concomitant type 2 DM.

scholarly journals THE RELATIONSHIP BETWEEN CALPROTECTIN AND PARAMETERS OF LIPID AND CARBOHYDRATE METABOLISM, ANTHROPOMETRIC AND INFLAMMATORY PARAMETERS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION AND DIABETES MELLITUS TYPE 2

2019 ◽  
Vol 19 (2) ◽  
pp. 16-18
Author(s):  
M. I. Zhuravlova
Keyword(s):  
Diabetes Mellitus ◽  
Myocardial Infarction ◽  
Insulin Resistance ◽  
Acute Myocardial Infarction ◽  
Carbohydrate Metabolism ◽  
Diabetes Mellitus Type 2 ◽  
The Body ◽  
Diabetes Mellitus Type ◽  
The Relationship

Nowadays, an acute myocardial infarction is one of the leading causes of mortality among the population. The EHS-DH registry data clearly illustrate the association between the comorbidities and high mortality following acute myocardial infarction during a year period of follow up. The pronounced influence of carbohydrate metabolism disturbances on the survival of such patients has already been reported. The aim of the study was to analyze the immune inflammation relationships based on assessing calprotectin and the parameters of lipid and carbohydrate metabolism, to evaluate the presence and nature of the relationship between these parameters and carbohydrate metabolism parameters based on the study of blood glucose, insulin and insulin resistance (by the indices HOMA, QUICKI, Caro), anthropometric indicators and inflammatory indicators (monocyte and neutrophile levels). Materials and methods. The study included 64 patients (mean age 65, 31 ± 1.62 years) with acute myocardial infarction and concomitant diabetes mellitus type 2. The design of the study included the primary laboratory investigation of patients during the first day since the onset of acute myocardial infarction with the elevation of the ST segment before the initiation of thrombolytic therapy or percutaneous intervention. The direct correlation between the calprotectin concentration and the HOMA insulin resistance index (R = 0.52; p <0.05), insulinemia (R = 0.57; p <0.05), fasting glycaemia (R = 0, 59; p <0.05), as well as inverse correlation relationships between the Caro index (R = 0.68; p <0.05) and the QUICKI index (R = 0.59; p <0.05) were found out. Moreover, a direct correlation between calprotectin and triglyceride levels (R = 0.31; p <0.05), and negative correlation with high density lipoprotein (R = 0.35; p <0.05) was established as well. The level of total cholesterol and low density lipoproteins showed no significant association with the proinflammatory factor (R = 0.12; p> 0.05 and R = 0.18; p> 0.05, respectively). Conclusions. The increase in the body mass index and the activity of serum monocytes and neutrophils is associated with high concentrations of calprotectin that is accompanied by disturbances of carbohydrate homeostasis towards the growth of insulin resistance and changes of lipidograms of proatherrogenic nature.

scholarly journals Perspectives on reducing mortality attributed to acute myocardial infarction among patients with type 2 diabetes mellitus in multicenter randomized trials

2016 ◽  
Vol 19 (2) ◽  
pp. 141-149 ◽  
Author(s):  
Sergey V. Kakorin ◽  
Ruben A. Iskandaryan ◽  
Ashot M. Mkrtumyan
Keyword(s):  
Diabetes Mellitus ◽  
Myocardial Infarction ◽  
Type 2 Diabetes ◽  
Acute Myocardial Infarction ◽  
Type 2 Diabetes Mellitus ◽  
Carbohydrate Metabolism ◽  
Scientific Literature ◽  
Review Of Literature

A review of the scientific literature was conducted to investigate reducing mortality from acute myocardial infarction (AMI) in patients with type 2 diabetes mellitus (T2DM). This included a review of literature comparing cardiovascular disease (CVD) treatment methods for AMI patients who have T2DM and those with normal carbohydrate metabolism. These treatments increase the life expectancy and greatly improve the quality of life of patients with acute myocardial infarction in both groups of patients. However, the risk of cardiovascular mortality in patients with T2DM compared with people with normal carbohydrate metabolism remains unchanged. The rapidly growing population of patients with T2DM will soon change our attitude towards the possibility of improving the prognosis and treatment of those with CVD. 

Abstract 3518: High Remnant Lipoprotein Levels Adversely Affect Short- and Long-term Outcomes for Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Takamitsu Nakamura ◽  
Mitsumasa Hirano ◽  
Yoshinobu Kitta ◽  
Yasushi Kodama ◽  
Akira Mende ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Long Term Outcomes ◽  
Remnant Lipoprotein ◽  
Type 2 Dm ◽  
Short And Long Term

Diabetes mellitus (DM) adversely affects prognosis in patients with acute myocardial infarction (AMI). Evidence shows that lipids-lowering therapy rather than glycemic control reduces macrovascular events in these patients, but it remains unclear which lipoprotein fractions contribute to negative effects. We previously showed that high levels of remnant lipoprotein, a triglyceride-rich lipoprotein, were an independent risk of future coronary events in patients with chronic coronary artery disease and DM. This study examined the hypothesis that remnant lipoproteinemia may adversely affect short- and long-term prognosis in patients with AMI and DM. Methods and Results: A prospective study was performed in 268 consecutive patients with Type 2 DM who were enrolled on day 5 after AMI. Fasting serum levels of remnant lipoproteins (remnant-like lipoprotein particles cholesterol; RLP-C) on day 5 after AMI were measured by an immunoseparation method. Adverse events, a composite of cardiac death, nonfatal MI, or recurrent unstable myocardial ischemia leading to unplanned revascularization therapy, were assessed during follow-up periods of 30 days and 1 year after AMI. Events rates were higher in patients with than without higher RLP-C levels (≥ 5.5 mg/dL, 50 th percentile of the distribution) during both short- and long-term follow-up periods (30 days post-MI, 8.2% [11/134 patients] vs. 2.2% [3/134 patients], p <0.05; 1 year post-MI, 15% [20] vs. 7.5% [10], p <0.05). In multivariate Cox hazard analyses, higher RLP-C levels were a significant predictor of adverse events during 30 days and 1 year independently of enrollment levels of glucose, LDL-C, and non-HDL-C (hazard ratios 2.1 and 1.7, 95% CI 1.8 – 3.9 and 1.3 – 4.0, respectively, both p<0.01). RLP-C levels were significantly correlated with C-reactive protein levels and intimal thickening of carotid artery at enrollment (r =0.30 and 0.39, respectively, both p<0.01). Conclusions: High remnant lipoprotein levels adversely affect short- and long-term outcomes in patients with AMI and Type 2 DM. The pro-inflammatory and pro-atherothrombogenic effects of remnant lipoprotein may contribute to coronary plaques instability in patients with AMI and Type 2 DM.

scholarly journals Prophylaxis of Reperfusion Complications in Treatment of Acute Myocardial Infarction in Type 2 Diabetes Mellitus Patients

2019 ◽  
Vol 15 (3) ◽  
pp. 4-18
Author(s):  
E. A. Kornienko
Keyword(s):  
Diabetes Mellitus ◽  
Myocardial Infarction ◽  
Type 2 Diabetes ◽  
Acute Myocardial Infarction ◽  
Lipid Peroxidation ◽  
Type 2 Diabetes Mellitus ◽  
Rheological Properties ◽  
Myocardial Contractility ◽  
Type 2 Dm

Purpose — to identify the possibility of improving the outcome of multimodality treatment of acute myocardial infarction (AMI) in type 2 diabetes mellitus (DM) patients by use of a succinate-containing drug.Materials and methods. The results of examination and treatment of 86 men aged 40 to 70 years with clinical diagnosis of AMI and concomitant type 2 DM were analyzed. The patients were split into two groups depending on use of the succinate-containing drug. Patients of the control group (38 men, 58.3±7.1 years old) received the standard treatment that included percutaneous coronary intervention (PCI). In the main group under study (48 men, 57.6±7.6 years old), the standard therapy complex was complemented with administration of a succinate-containing drug (1.5% succinic acid solution), which was administered first 30–60 minutes prior to PCI intravenously at a dose of 10–12 ml/kg; then, daily once a day, for 5 days at a dose of 5–6 ml/kg. Peculiarities of the AMI clinical course, dynamics of myocardial contractility, values of acid-base balance (ABB), glucose and lactate content, lipid peroxidation (LPO) and antioxidant system (AOS), rheological properties of the blood were evaluated.Results. During AMI type 2 DM patients developed compensated metabolic lactic acidosis and oxidative distress that manifested in considerable activation of LPO and insufficient activity of the enzymatic component of AOS, blood viscosity grew, elasticity of red blood cells fell. Decreased local and global myocardial contractility was noted as well. During PCI in this category of patients, cardiac rhythm disorders developed in 47.4% of cases, 23.7% of which were life threatening, such as multifocal ventricular extra systole and ventricular fibrillation. Conclusion. Administration of a succinate-containing drug during performance of PCI provided correction of the lipid peroxidation processes and rheological properties of the blood in the population studied, facilitated improvement of left ventricle’s systolic and diastolic function, reduced the risk of reperfusion complications.

Abstract 2605: Hypoglycemia Does Not Increase Long-term Mortality Or Morbidity In Diabetic Patients With Myocardial Infarction. A Report From The Digami 2 Trial.

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Linda G Mellbin ◽  
Klas Malmberg ◽  
Anders Waldenstrom ◽  
Hans Wedel ◽  
Lars Ryden
Keyword(s):  
Myocardial Infarction ◽  
Blood Glucose ◽  
Negative Impact ◽  
Significant Risk ◽  
Significant Risk Factor ◽  
Diabetic Patients ◽  
Type 2 Dm ◽  
Hazard Ratios

Aims Tight, insulin-based glucose control is recommended to diabetic patients (DM pat) with acute myocardial infarction (AMI). A potential draw-back would be if insulin induced hypoglycaemia (HG) had a negative impact of future prognosis. Methods 1253 pat (mean age 68 years; 67% males) with type 2 DM and suspect AMI were followed for a median of 2.1 years. 947 were randomised to insulin infusion during at least 24 hours while 306 were treated routinely. HG (blood glucose<3.0 mmol/L with or without symptoms) was recorded during hospitalisation. Unadjusted and adjusted (age, sex, smoking, previous MI and heart failure, renal function, duration of DM, coronary interventions, blood glucose at randomisation) Hazard Ratios (HR) and 95% Confidence Intervals (CI) for cardiovascular events (CVE = death, MI or stroke) during follow up were calculated. Results 153 pat (12.2%) experienced HG. During the first 24 hours 111 (11.7%) insulin-treated pat experienced HG (symptomatic 23.4%) compared with 3 (1.0%) pat on routine treatment (symptomatic 33.3%). As outlined in the figure HG was not an independent predictor of subsequent CVE. Conclusion Insulin induced HG was not a significant risk factor for subsequent CVE in AMI-pat with type 2 DM. Hypoglycaemic seem to identify patients at high risk for other reasons.

Sign in / Sign up

Export Citation Format

Share Document